|Articles|May 26, 2021

Many Hospitalized COVID-19 Patients Discharged in Worse Physical Condition

Author(s)Killian Meara

Nearly half of COVID-19 patients never received rehabilitation evaluation and 20% lost daily living abilities.

A recent study conducted by investigators from Michigan Medicine at the University of Michigan has discovered that nearly half of the patients who were hospitalized with COVID-19 were discharged with significant loss of ability and functional decline.

Results from the study were published in PM&R: The Journal of Injury, Function and Rehabilitation.

"Physicians and others in the health care system were working appropriately to discharge patients," Alecia K. Daunter, lead author on the study said. "They needed to keep patients safe while maximizing available beds and minimizing exposure to staff. I think that contributed to many people not being assessed by a therapist or PM&R physician. So, the things we do to in the hospital to maximize functioning, like mobility interventions and assessing activities of daily living were, not happening as often."

For the study, the team of investigators analyzed charts of nearly 300 adult patients who were hospitalized for COVID-19 at Michigan Medicine between March and April of 2020.

The investigators reviewed discharge locations, therapy needs at the time of release and if they needed durable medical equipment or other services.

Findings from the study demonstrated that 40% of COVID-19 patients never had a rehabilitation evaluation while hospitalized. Of the COVID-19 survivors who experienced functional decline, 80% were referred for additional therapy after being discharged.

Additionally, almost 20% of all patients lost ability to the point where they were not able to live independently after their release.

"These problems are frequent, and the stakes are pretty high if we miss them, or allow them to progress during hospitalization," Daunter said. "Some of these people were working and many were living independently. To lose that level of function is meaningful. We want to make sure we're addressing those needs, not just looking at the black and white, survival or death."


Related to this article

Measles Update: October 30, 2026
The latest CDC numbers show a 5.8% increase in measles cases from week-to-week, bringing the 2026 US total to more than double the amount seen in all of 2025 with 2 months left in the year.
Cefiderocol Continues to Show Activity Against Resistant Gram-Negative Infections
Shionogi data presented at IDWeek 2026 demonstrated a 76.7% clinical response with cefiderocol in carbapenem-resistant respiratory infections and high in vitro activity against resistant P aeruginosa VAP isolates. Christine Slover, PharmD, vice president, Infectious Diseases US Medical Affairs, Shionogi, offers insights on the data as well as clinical considerations for providers when weighing the antibiotic for patients.
FAQ: Shamonda Virus
As France confirms the first documented human Shamonda virus infection, a fatal encephalitis in a stem cell transplant recipient, this FAQ explains what the virus is, where it has spread, how the case was diagnosed, how the patient was likely infected and what clinicians should watch for.
ID Week Highlights Part 1
In this first IDWeek 2026 roundup, oral olorofim matched AmBisome in invasive aspergillosis, aztreonam-avibactam held activity as MBL-producing CRE rose, pritelivir cut hospitalizations in refractory HSV, and zelicapavir shortened RSV symptoms in high-risk adults.